Biomarkers in Inflammatory bowel disease with antibody therapy
Two types of inflammatory bowel disease, Ulcerative colitis and Crohn’s disease. A challenge in IBD development is that many drugs show systemic PK and PD but fail in the intestinal mucosa. Most companies focus on Ulcerative colitis due to a) homogenous biology, b) access to tissue, c) established endpoints and d) lower variability in translational…